Our analysis demonstrates that CMS’s coverage processes for breakthrough devices demonstrate product class and disease state disparities. These disparities contradict mental health parity statute, CMS Administrator Brooks-LaSure’s focus on equity, and President Biden’s charge to improve brain health.
